31.07.2015 Views

Advances in the stereoselective synthesis of antifungal agents and ...

Advances in the stereoselective synthesis of antifungal agents and ...

Advances in the stereoselective synthesis of antifungal agents and ...

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Chapter 1 15s<strong>in</strong>gle enantiomers <strong>and</strong> <strong>the</strong> racemic mixture virtually showed <strong>the</strong> same<strong>antifungal</strong> activity 50 .The antimicrobial activity <strong>of</strong> Econazole 5b has been shown to besimilar to that <strong>of</strong> 5a aga<strong>in</strong>st dermatophytes, pathogenic yeasts, dimorphic<strong>and</strong> filamentous as well as gram positive bacteria 51,52 .Isoconazole 5c, 1- [ 2, 4- dichloro -β- ( 2, 6 - dichloro benzyloxy )phenylethyl] imidazole nitrate, is an antifugal imidazole structurally related toboth Miconazole 5a <strong>and</strong> Econazole 5b, produced by JanssenPharmaceuticals.No <strong>in</strong>formations are available on <strong>the</strong> enantioselective syn<strong>the</strong>sis orchemical resolution <strong>of</strong> this compound, nei<strong>the</strong>r <strong>the</strong> antimicotic activity <strong>of</strong> as<strong>in</strong>gle enantiomer.Isoconazole 5c has been demonstrated to have a broad activityspectrum <strong>in</strong> vitro aga<strong>in</strong>st dermatophytes, pathogenic yeasts, pathogenicfilamentous fungi , gram positive bacteria <strong>and</strong> tricomonas 53 . It is veryeffective <strong>in</strong> <strong>the</strong> treatment <strong>of</strong> experimentally <strong>in</strong>duced <strong>in</strong>fections follow<strong>in</strong>gtopical application. In fact, this compound has been developed <strong>and</strong>marketed for <strong>the</strong> topical treatment <strong>of</strong> vag<strong>in</strong>al c<strong>and</strong>idiasis 53 .Tioconazole, 1-[2-[ (2-chloro-3-thienyl) methoxy]-2-(2,4dichlorophenylethyl]-1H-imidazole 5d is a substituted imidazole derivate sy<strong>the</strong>sizedby Pfizer. 5d has been shown to be 4 fold more active than 5a aga<strong>in</strong>stC<strong>and</strong>ida sp. while it is comparable to 5a <strong>in</strong> its <strong>in</strong>hibitory activity aga<strong>in</strong>stAspergillus sp. 54 . The ma<strong>in</strong> use <strong>of</strong> this drug is as a topical agent for <strong>the</strong>treatment <strong>of</strong> sk<strong>in</strong> mycose, vag<strong>in</strong>al c<strong>and</strong>idiasis <strong>and</strong> tricomoniasis 54 .1.2.2.3. Bifonazole <strong>and</strong> its analogs 6a-d.Bifonazole 6a <strong>and</strong> its analogues 6b-d are shown <strong>in</strong> figure 1.12.Bifonazole, 1-[(4-biphenyl)phenylmethyl]-1H-imidazole 6a, is an imidazolederivative syn<strong>the</strong>sized by <strong>the</strong> Bayer AG <strong>in</strong> racemic form 55 . Up to now <strong>the</strong>reare no reports regard<strong>in</strong>g its <strong>stereoselective</strong> syn<strong>the</strong>sis.There are also nopharmacological <strong>in</strong>formations available regard<strong>in</strong>g <strong>the</strong> activities <strong>of</strong> <strong>the</strong> s<strong>in</strong>gleenantiomers.Bifonazole has been shown to have a broad spectrum <strong>of</strong> <strong>antifungal</strong>activity <strong>in</strong> vitro aga<strong>in</strong>st many pathogenic yeasts, dimorfic pathogens,dermatophytes <strong>and</strong> pathogenic filamentouses fungi 56 .

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!